Skip to main navigation
Biohaven Pharmaceutucals Biohaven Pharmaceutucals
  • About
    • Overview
    • Our People
      • Meet our CEO
    • Board of Directors
    • Scientific Advisory Board
    • Global Collaboration
  • Pipeline
    • Overview
    • Clinical Programs
      • Kv7
      • GLUTAMATE
      • MYOSTATIN
      • CD-38
    • Discovery Research
      • Kv7 Platform
      • TRPM3
      • MATE™ Platform
      • MoDE™ Platform
      • ARM™ Platform
      • UC1MT
    • Clinical Trials
    • Publications
  • Media
    • Top News
    • Media Resources
  • Investors
    • Overview
    • Press Releases
    • Events and Presentations
      • Upcoming and Recent Events
    • Financial Filings
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
    • Corporate Governance
      • Governance Documents
      • Committees
    • Contact
  • Commitment
    • Overview
    • Early Access Program
  • Careers
    • Overview
    • Openings
  • Contact
Search
  • About
    • Overview
    • Our People
      • Meet our CEO
    • Board of Directors
    • Scientific Advisory Board
    • Global Collaboration
  • Pipeline
    • Overview
    • Clinical Programs
      • Kv7
      • GLUTAMATE
      • MYOSTATIN
      • CD-38
    • Discovery Research
      • Kv7 Platform
      • TRPM3
      • MATE™ Platform
      • MoDE™ Platform
      • ARM™ Platform
      • UC1MT
    • Clinical Trials
    • Publications
  • Media
    • Top News
    • Media Resources
  • Investors
    • Overview
    • Press Releases
    • Events and Presentations
      • Upcoming and Recent Events
    • Financial Filings
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
    • Corporate Governance
      • Governance Documents
      • Committees
    • Contact
  • Commitment
    • Overview
    • Early Access Program
  • Careers
    • Overview
    • Openings
  • Contact
Gaurav Munj 2022-03-04T06:42:16+00:00

Press Releases

Site - Investor Relations Nav

  • Overview
  • Press Releases
  • Events and Presentations
  • Financial Filings
  • Stock Information
  • Corporate Governance
  • Contact
    • Upcoming and Recent Events
    • Corporate Presentation
    • SEC Filings
    • Stock Quote & Chart
    • Governance Documents
    • Committees
March 23, 2023
Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments
March 22, 2023
Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders
March 14, 2023
Biohaven Announces Presentation at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
February 21, 2023
Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy
January 6, 2023
Biohaven to Present at the 41st Annual J.P. Morgan Healthcare Conference

BIOHAVEN (BHVN)

Volume
Market Cap
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Biohaven white logo

Footer Links - Column 1

  • About
    • Overview
    • Our People
    • Board of Directors
    • Scientific Advisory Board
    • Global Collaboration

Footer Links - Column 2

  • Media
    • Top News
    • Media Resources
  • COMMITMENT
    • Overview
    • Early Access Programs

Footer Links - Column 3

  • Pipeline
    • Overview
    • Clinical Programs
    • Discovery Research
    • Clinical Trials
    • Publications
  • CAREERS
    • Openings
  • CONTACT

Footer Mobile Links

  • About
  • Pipeline
  • Media
  • Investors
  • Commitment
  • Careers
  • Contact

Footer Links - Column 4

  • INVESTORS
    • Overview
    • Press Releases
    • Events and Presentations
    • Financial Filings
    • Stock Information
    • Corporate Governance
    • Contact

BHVN


LISTED


NYSE

Site - Social Media

BIOHAVEN, LTD.

215 Church Street, New Haven, CT 06510

©2023 Biohaven, Ltd.

  • TERMS & CONDITIONS
  • PRIVACY
  • SOCIAL
  • COOKIES